Biotech Values

[DewDiligence]

RVNC announces delay in phase-3 RT001 trial in crow’s feet indication:

http://finance.yahoo.com/news/revance-therapeutics-provides-rt001-clinical-200100410.html

Revance Therapeutics…today announced that the company has initiated a study to confirm this quarter the successful transfer of production of the topical RT001 drug product to Revance's U.S. commercial manufacturing facility. Following successful confirmation of this transfer, Revance plans to initiate its first U.S. Phase 3 RT001 pivotal study for the treatment of lateral canthal (crow's feet) lines, with results now anticipated during the first quarter of 2015. Previously, Revance expected to report results from the first U.S. Phase 3 pivotal study by the end of 2014.

This is the lead indication for RT001, which is a topical formulation of type-A botulinum toxin.